New anticancer agents in clinical development

J. Eckardt, G. Eckhardt, M. Villalona-Calero, R. Drengler, D. Von Hoff

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; the paclitaxel analog docetaxel; gemcitabine, an antimetabolite structurally related to cytarabine; and fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors. Another exciting approach to cancer treatment is the use of agents that induce a less malignant state by altering cellular phenotype. Such agents include angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.

Original languageEnglish (US)
Pages (from-to)1191-1199
Number of pages9
JournalONCOLOGY
Volume9
Issue number11
StatePublished - Dec 18 1995

Fingerprint

irinotecan
9-aminocamptothecin
docetaxel
gemcitabine
Antineoplastic Agents
Topoisomerase I Inhibitors
Topotecan
Antimetabolites
Camptothecin
Thymidylate Synthase
Angiogenesis Inhibitors
Cytarabine
Prodrugs
Paclitaxel
Fluorouracil
Genetic Therapy
Biochemistry
Signal Transduction
Neoplasms
Phenotype

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Eckardt, J., Eckhardt, G., Villalona-Calero, M., Drengler, R., & Von Hoff, D. (1995). New anticancer agents in clinical development. ONCOLOGY, 9(11), 1191-1199.

New anticancer agents in clinical development. / Eckardt, J.; Eckhardt, G.; Villalona-Calero, M.; Drengler, R.; Von Hoff, D.

In: ONCOLOGY, Vol. 9, No. 11, 18.12.1995, p. 1191-1199.

Research output: Contribution to journalReview article

Eckardt, J, Eckhardt, G, Villalona-Calero, M, Drengler, R & Von Hoff, D 1995, 'New anticancer agents in clinical development', ONCOLOGY, vol. 9, no. 11, pp. 1191-1199.
Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R, Von Hoff D. New anticancer agents in clinical development. ONCOLOGY. 1995 Dec 18;9(11):1191-1199.
Eckardt, J. ; Eckhardt, G. ; Villalona-Calero, M. ; Drengler, R. ; Von Hoff, D. / New anticancer agents in clinical development. In: ONCOLOGY. 1995 ; Vol. 9, No. 11. pp. 1191-1199.
@article{cae069bfd1c944ef8f79ff7b564ef9f5,
title = "New anticancer agents in clinical development",
abstract = "A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; the paclitaxel analog docetaxel; gemcitabine, an antimetabolite structurally related to cytarabine; and fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors. Another exciting approach to cancer treatment is the use of agents that induce a less malignant state by altering cellular phenotype. Such agents include angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.",
author = "J. Eckardt and G. Eckhardt and M. Villalona-Calero and R. Drengler and {Von Hoff}, D.",
year = "1995",
month = "12",
day = "18",
language = "English (US)",
volume = "9",
pages = "1191--1199",
journal = "Oncology (Williston Park, N.Y.)",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "11",

}

TY - JOUR

T1 - New anticancer agents in clinical development

AU - Eckardt, J.

AU - Eckhardt, G.

AU - Villalona-Calero, M.

AU - Drengler, R.

AU - Von Hoff, D.

PY - 1995/12/18

Y1 - 1995/12/18

N2 - A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; the paclitaxel analog docetaxel; gemcitabine, an antimetabolite structurally related to cytarabine; and fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors. Another exciting approach to cancer treatment is the use of agents that induce a less malignant state by altering cellular phenotype. Such agents include angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.

AB - A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; the paclitaxel analog docetaxel; gemcitabine, an antimetabolite structurally related to cytarabine; and fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors. Another exciting approach to cancer treatment is the use of agents that induce a less malignant state by altering cellular phenotype. Such agents include angiogenesis inhibitors, differentiating agents, signal transduction inhibitors, and gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028807533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028807533&partnerID=8YFLogxK

M3 - Review article

C2 - 8703688

AN - SCOPUS:0028807533

VL - 9

SP - 1191

EP - 1199

JO - Oncology (Williston Park, N.Y.)

JF - Oncology (Williston Park, N.Y.)

SN - 0890-9091

IS - 11

ER -